Clinical Trial Update: The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIV [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and effectiveness of ganciclovir for CMV-related eye and GI diseases in HIV patients; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Retinitis
• Gastrointestinal Diseases
• HIV Infection Management

Drugs mentioned

• GANCICLOVIR (GANCICLOVIR SODIUM)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Cytomegalovirus Retinitis, HIV Infections | Phase 2 | Status: COMPLETED